With the increasing application of emerging technologies like AI in healthcare, better care outcomes can be achieved in more efficient and timely fashion. This displays a great example of how this pandemic has fast forwarded the behaviour change and that the world is now even more ready and committed to support innovative ways to fight this deadly pandemic.
The US Food and Drug Administration (FDA) has granted emergency use authorization (EUA) to the first machine learning-based Covid-19 non-diagnostic screening device. The Tiger Tech COVID Plus Monitor is an armband with embedded light sensors and a small computer processor which identifies biomarkers that are typical to conditions like hypercoagulation or blood clotting. It will be used by trained personnel to prevent exposure and spread of the virus. The device identifies the SARS-CoV-2 virus, along with other conditions and allergies in asymptomatic individuals over the age of 5.
Stimdia Medical, a company that specialises in the development of lung pacing devices, has received FDA’s approval for its pdSTIM system. The Breakthrough Device designation allows the device to be used to treat difficult conditions and gain regular access and priority to the FDA. The system can be used in treating high risk Covid patients, to recondition the diaphragm and strengthen the primary muscle used in respiration. The device is expected to reduce weaning time for patients on mechanical ventilation.
The UK government is currently developing a test genotype assay test, which will be able to detect Covid-19 variants of concerns from coronavirus test samples. According to the UK government’s health ministry, the test is expected to halve the time required to detect Covid-19 variants and will be used alongside standard testing to identify cases more rapidly, thereby curbing the virus spread and easing restrictions.